A5005309444- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Lung Cancer Treatments and Mutations
- Acute Myeloid Leukemia Research
- Viral-associated cancers and disorders
- Cancer Immunotherapy and Biomarkers
- CNS Lymphoma Diagnosis and Treatment
- HER2/EGFR in Cancer Research
- Ovarian cancer diagnosis and treatment
- Endometrial and Cervical Cancer Treatments
- Vascular Tumors and Angiosarcomas
- Sarcoma Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Colorectal Cancer Treatments and Studies
- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- Chronic Myeloid Leukemia Treatments
- Inflammatory Biomarkers in Disease Prognosis
- Lung Cancer Research Studies
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cancer Diagnosis and Treatment
- Amyloidosis: Diagnosis, Treatment, Outcomes
- CAR-T cell therapy research
- Lung Cancer Diagnosis and Treatment
Cukurova University
2016-2025
Pfizer (United States)
2024
Pfizer (United Kingdom)
2024
AstraZeneca (Brazil)
2024
Novartis (Switzerland)
2024
Weatherford College
2024
Roche (Switzerland)
2024
Sağlık Bilimleri Üniversitesi
2020-2023
Mersin Üniversitesi
2023
Adana Hospital
2023
AbstractThirty-two cases of granulocytic sarcoma (GS) are reported in this paper. Age range was from 16 – 70 years. GS accompanied by AML 13 cases, ALL (My+) one case, CML 11 and MDS two cases. diagnosed simultaneously with leukemia five preceded the eight. Lymph node soft tissue were most commonly detected localizations. Seven had first been as NHL. Histopathologically blastic, immature mature variants found 11, nine respectively overall survival shortest blastic type. Myeloperoxidase...
Abstract Bone marrow necrosis (BMN) is a relatively uncommon clinicopathologic entity. The etiology diverse, and malignancy, especially hematopoietic in origin, the most common underlying disease of BMN. In this retrospective analysis, cases with BMN were re‐evaluated for etiology, histopathologic details, clinical manifestations. last 8 years, 23 detected among 1,083 bone (BM) biopsies, prevalence was found to be 2.2%. Three these children, 20 adults. Sixteen (80%) had malignant disease,...
There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which oncologists prefer patients with disease progression under CDKi. In addition, we show the effectiveness of systemic treatments CDKi and whether there a survival difference between hormonal (monotherapy vs. mTOR-based).A total 609 from 53 centers were included study....
To compare the long-term efficacy of pneumatic compression and low-level laser therapies in management postmastectomy lymphoedema.Randomized controlled trial.Department Physical Medicine Rehabilitation Cukurova University, Turkey.Forty-seven patients with lymphoedema were enrolled study.Patients randomly allocated to (group I, n=24) II, n=23) groups. Group I received 2 hours therapy group II 20 minutes for four weeks. All advised perform daily limb exercises.Demographic features, difference...
The effect of Blastocystis hominis (B. hominis) in both immunocompetent and immunocompromised subjects has been the subject debate recent years, mostly response to its unknown pathogenicity frequency occurrence. We performed a non-randomised, open labelled, single institute study our hospital order investigate clinical significance B. patients suffering from hematological malignancy (HM) who displayed symptoms gastrointestinal diseases during period chemotherapy-induced neutropenia. presence...
Background Trastuzumab is a recombinant humanized monoclonal antibody used to treat human epidermal growth factor receptor 2 positive breast cancer, with recognized associated cardiotoxicity. In this retrospective observational study, we investigated cardiotoxicity on clinical outcomes using trastuzumab in women referred our clinic. Materials and methods The study was made up of 111 2-overexpressing cancer who received the Medical Oncology Department, between 2010 2013. Results A > 10%...
Giant cell tumor of bone (GCT) is a primary, osteolytic, benign the bone. Surgery commonly used treatment; however, recurrence remains problem. Receptor activator nuclear factor kappa B (RANKL) responsible for formation osteoclastic cells. Discovery RANKL and its human monoclonal antibody, denosumab, led to use denosumab treatment GCT. The aim this study was evaluate clinical pathological results GCT with assess adverse effect profile rate.Thirteen patients 14 lesions were enrolled in study....
Aim: To evaluate the prognostic significance of neutrophil lymphocyte ratio, nutritional index, systemic immune-inflammation index (SII) and B2M in Hodgkin Lymphoma (HL). Materials & methods: Neutrophil–lymphocyte SII were analyzed to assess their value via Kaplan–Meier method Cox regression analysis 122 HL patients, retrospectively. Results: was found have highest area under curve most sensitive specific among all markers. In univariate analyses, four parameters for overall survival...
Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase as the first-line standard-of-care for patients hormone receptor-positive, HER2-negative metastatic breast cancer.
Leukaemia cutis (LC) and leukaemic vasculitis (LV) are uncommon but important features of haematological malignancy.We aimed to evaluate clinicopathological a series such cases.Thirty-four patients with LC were studied. Nineteen had acute myeloblastic leukaemia, six lymphoblastic three myelodysplastic syndrome-refractory anaemia excess blast in transformation, non-Hodgkin's lymphoma phase, two chronic lymphocytic leukaemia one multiple myeloma.Cutaneous lesions widely dispersed 15 patients,...
AbstractAngiogenesis has a major role in the pathogenesis of malignancies. Studies involving angiogenesis have been most commonly performed solid tumors. However, studies related to hemapoietic neoplasia and are relatively limited. We investigated non-Hodgkin's lymphomas (NHLs) its relation with clinical histopathologic prognostic indicators. In this respect, markers were evaluated 71 patients NHL these compared other indicators including age, gender, histological grade, stage, extranodal...
The PRAME (preferentially expressed antigen of melanoma) gene has been shown to be in high levels some solid tumors and hemopoietic neoplasias but not or only weakly normal tissues. It encodes an recognized by autologous cytolytic T lymphocytes. is a good candidate for tumor immunotherapy useful marker detection minimal residual disease (MRD). In this study, mRNA using real-time RT-PCR was studied 74 adult cases with acute leukemia-68 had de-novo leukemia, 3 chronic myeloid leukemia-blastic...